Literature DB >> 29303449

The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis.

Debra A Goldman1, Koos Hovinga2,3, Anne S Reiner1, Yoshua Esquenazi2,4, Viviane Tabar2, Katherine S Panageas1.   

Abstract

OBJECTIVEPrevious studies assessed the relationship between repeat resection and overall survival (OS) in patients with glioblastoma, but ignoring the timing of repeat resection may have led to biased conclusions. Statistical methods that take time into account are well established and applied consistently in other medical fields. The goal of this study was to illustrate the change in the effect of repeat resection on OS in patients with glioblastoma once timing of resection is incorporated.METHODSThe authors conducted a retrospective study of patients initially diagnosed with glioblastoma between January 2005 and December 2014 who were treated at Memorial Sloan Kettering Cancer Center. Patients underwent at least 1 craniotomy with both pre- and postoperative MRI data available. The effect of repeat resection on OS was assessed with time-dependent extended Cox regression controlling for extent of resection, initial Karnofsky Performance Scale score, sex, age, multifocal status, eloquent status, and postoperative treatment.RESULTSEighty-nine (55%) of 163 patients underwent repeat resection with a median time between resections of 7.7 months (range 0.5-50.8 months). Median OS was 18.8 months (95% confidence interval [CI] 16.3-20.5 months) from initial resection. When timing of repeat resection was ignored, repeat resection was associated with a lower risk of death (hazard ratio [HR] 0.62, 95% CI 0.43-0.90, p = 0.01); however, when timing was taken into account, repeat resection was associated with a higher risk of death (HR 2.19, 95% CI 1.47-3.28, p < 0.001).CONCLUSIONSIn this study, accounting for timing of repeat resection reversed its protective effect on OS, suggesting repeat resection may not benefit OS in all patients. These findings establish a foundation for future work by accounting for timing of repeat resection using time-dependent methods in the evaluation of repeat resection on OS. Additional recommendations include improved data capture that includes mutational data, development of algorithms for determining eligibility for repeat resection, more rigorous statistical analyses, and the assessment of additional benefits of repeat resection, such as reduction of symptom burden and enhanced quality of life.

Entities:  

Keywords:  CI = confidence interval; EOR = extent of resection; HR = hazard ratio; HSRT = hypofractionated stereotactic radiation therapy; KM = Kaplan-Meier; KPS = Karnofsky Performance Scale; OS = overall survival; glioblastoma; oncology; proportional hazards model; repeat surgery; survival analysis; time-dependent model

Mesh:

Year:  2018        PMID: 29303449      PMCID: PMC6392195          DOI: 10.3171/2017.6.JNS17393

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  31 in total

Review 1.  Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation.

Authors:  Simona Iacobelli
Journal:  Bone Marrow Transplant       Date:  2013-03       Impact factor: 5.483

2.  Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit.

Authors:  Patrick A Tully; Andrew J Gogos; Craig Love; Danny Liew; Katharine J Drummond; Andrew P Morokoff
Journal:  Neurosurgery       Date:  2016-11       Impact factor: 4.654

3.  Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids.

Authors:  Eduard H Panosyan; Joseph L Lasky; Henry J Lin; Albert Lai; Yang Hai; Xiuqing Guo; Michael Quinn; Stanley F Nelson; Timothy F Cloughesy; P Leia Nghiemphu
Journal:  J Neurooncol       Date:  2016-02-27       Impact factor: 4.130

4.  A combinatorial radiographic phenotype may stratify patient survival and be associated with invasion and proliferation characteristics in glioblastoma.

Authors:  Arvind Rao; Ganesh Rao; David A Gutman; Adam E Flanders; Scott N Hwang; Daniel L Rubin; Rivka R Colen; Pascal O Zinn; Rajan Jain; Max Wintermark; Justin S Kirby; C Carl Jaffe; John Freymann
Journal:  J Neurosurg       Date:  2015-10-16       Impact factor: 5.115

5.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

6.  An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.

Authors:  Mark E Oppenlander; Andrew B Wolf; Laura A Snyder; Robert Bina; Jeffrey R Wilson; Stephen W Coons; Lynn S Ashby; David Brachman; Peter Nakaji; Randall W Porter; Kris A Smith; Robert F Spetzler; Nader Sanai
Journal:  J Neurosurg       Date:  2014-01-31       Impact factor: 5.115

7.  An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.

Authors:  Haley Gittleman; Daniel Lim; Michael W Kattan; Arnab Chakravarti; Mark R Gilbert; Andrew B Lassman; Simon S Lo; Mitchell Machtay; Andrew E Sloan; Erik P Sulman; Devin Tian; Michael A Vogelbaum; Tony J C Wang; Marta Penas-Prado; Emad Youssef; Deborah T Blumenthal; Peixin Zhang; Minesh P Mehta; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

8.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Authors:  Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

9.  Analysis of survival by tumor response.

Authors:  J R Anderson; K C Cain; R D Gelber
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

10.  Canadian recommendations for the treatment of glioblastoma multiforme.

Authors:  W P Mason; R Del Maestro; D Eisenstat; P Forsyth; D Fulton; N Laperrière; D Macdonald; J Perry; B Thiessen
Journal:  Curr Oncol       Date:  2007-06       Impact factor: 3.677

View more
  14 in total

1.  Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review.

Authors:  David Botros; Hayden Dux; Carrie Price; Adham M Khalafallah; Debraj Mukherjee
Journal:  Neurosurg Rev       Date:  2020-06-13       Impact factor: 3.042

2.  Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit.

Authors:  Mateo Tomas Fariña Nuñez; Pamela Franco; Debora Cipriani; Nicolas Neidert; Simon P Behringer; Irina Mader; Daniel Delev; Christian Fung; Jürgen Beck; Roman Sankowski; Nils Henrik Nicolay; Dieter Henrik Heiland; Oliver Schnell
Journal:  J Neurooncol       Date:  2020-01-13       Impact factor: 4.130

3.  Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma.

Authors:  Francesco Pasqualetti; Nicola Montemurro; Isacco Desideri; Mauro Loi; Noemi Giannini; Giovanni Gadducci; Giulia Malfatti; Martina Cantarella; Alessandra Gonnelli; Sabrina Montrone; Luca Visani; Cristian Scatena; Antonio Giuseppe Naccarato; Paolo Perrini; Carlo Gambacciani; Orazio Santonocito; Riccardo Morganti; Fabiola Paiar
Journal:  Acta Neurol Belg       Date:  2021-08-16       Impact factor: 2.396

4.  Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.

Authors:  Antonio Dono; Ping Zhu; Emma Holmes; Takeshi Takayasu; Jay-Jiguang Zhu; Angel I Blanco; Sigmund Hsu; Meenakshi B Bhattacharjee; Leomar Y Ballester; Dong H Kim; Yoshua Esquenazi; Nitin Tandon
Journal:  J Neurooncol       Date:  2022-01-08       Impact factor: 4.506

5.  Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastoma.

Authors:  Theresa A Cook; Dasantha T Jayamanne; Helen R Wheeler; Matthew H F Wong; Jonathon F Parkinson; Raymond J Cook; Marina A Kastelan; Nicola J Cove; Christopher Brown; Michael F Back
Journal:  Neurooncol Pract       Date:  2021-06-09

6.  PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.

Authors:  Antonio Dono; Sonali Mitra; Mauli Shah; Takeshi Takayasu; Jay-Jiguang Zhu; Nitin Tandon; Chirag B Patel; Yoshua Esquenazi; Leomar Y Ballester
Journal:  J Neurooncol       Date:  2021-04-21       Impact factor: 4.130

7.  ARL3 is downregulated and acts as a prognostic biomarker in glioma.

Authors:  Yulin Wang; Weijiang Zhao; Xin Liu; Gefei Guan; Minghua Zhuang
Journal:  J Transl Med       Date:  2019-06-24       Impact factor: 5.531

8.  Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study.

Authors:  Debra A Goldman; Anne S Reiner; Eli L Diamond; Lisa M DeAngelis; Viviane Tabar; Katherine S Panageas
Journal:  Neurooncol Adv       Date:  2020-11-29

9.  GammaTile® brachytherapy in the treatment of recurrent glioblastomas.

Authors:  Dominic J Gessler; Elizabeth C Neil; Rena Shah; Joseph Levine; James Shanks; Christopher Wilke; Margaret Reynolds; Shunqing Zhang; Can Özütemiz; Mehmet Gencturk; Mark Folkertsma; W Robert Bell; Liam Chen; Clara Ferreira; Kathryn Dusenbery; Clark C Chen
Journal:  Neurooncol Adv       Date:  2021-12-27

10.  Preoperative Prediction Nomogram Based on Integrated Profiling for Glioblastoma Multiforme in Glioma Patients.

Authors:  Wei Wu; Zhong Deng; Wahafu Alafate; Yichang Wang; Jianyang Xiang; Lizhe Zhu; Bolin Li; Maode Wang; Jia Wang
Journal:  Front Oncol       Date:  2020-10-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.